A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
BIO-TECHNE Corp
TECH
$11.4B
Mkt Cap
$71.60
-0.24%
BIO-TECHNE Corp (TECH) has a current P/E ratio of 138.1, compared to its historical median P/E of 47.1. The stock is currently considered Expensive based on its historical valuation range.
BIO-TECHNE Corp (TECH) has a 5-year average return on invested capital (ROIC) of 10.8%. This indicates solid capital allocation.
BIO-TECHNE Corp (TECH) has a market capitalization of $11.2B. It is classified as a large-cap stock.
Yes, BIO-TECHNE Corp (TECH) pays a dividend with a trailing twelve-month yield of 0.44%. The company also returns capital through share buybacks, with a buyback yield of 0.89%.
Based on historical P/E analysis, BIO-TECHNE Corp (TECH) appears expensive. The current P/E of 138.1 is 193% above its historical median of 47.1. The estimated fair value CAGR (P/E method) is -1.1%.
BIO-TECHNE Corp (TECH) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
BIO-TECHNE Corp (TECH) reported annual revenue of $1.2 billion in its most recent fiscal year, based on SEC EDGAR filings.
Bio-Techne develops, manufactures, and sells life science reagents, instruments, and services for research, diagnostics, and bioprocessing markets globally. The company operates through two segments: Protein Sciences (approximately 72% of fiscal 2025 net sales), which includes specialized proteins, antibodies, small molecules, tissue culture sera, and proteomic analytical instruments for researchers and pharmaceutical/biotech companies; and Diagnostics and Spatial Biology (approximately 28% of fiscal 2025 net sales), which offers in-situ hybridization assays, exosome-based liquid biopsy diagnostics, and diagnostic reagents for clinical and research applications. Bio-Techne manufactures most products itself across multiple facilities in North America, the U.K., Canada, Switzerland, and China, and distributes directly to customers in North America, Europe, and China, as well as through Thermo Fisher Scientific and third-party distributors globally. The company's competitive position is built on high-quality biological reagents, proprietary proteomic platforms, and spatial biology solutions, with no single end-user customer representing more than 10% of segment sales. Bio-Techne serves diverse customers including academic researchers, pharmaceutical and biotech companies, contract research organizations, and diagnostic instrument manufacturers, with a strategic focus on cell and gene therapy, proteomic analysis, spatial biology, and precision diagnostics as high-growth verticals representing 47% of total revenue as of fiscal 2025.
【Market stabilization and biotech recovery】 Management expects gradual improvement in end-market conditions as biotech funding translates into customer spending, academic markets normalize, and company-specific timing headwinds from cell therapy customers roll off in fiscal 2027. The spatial biology COMET platform is positioned for continued growth with record backlog exiting Q3 fiscal 2026, and GMP protein portfolio growth of nearly 50% year-over-year (excluding Fast Track cell therapy customers) is viewed as constructive for fiscal 2027 given typical two to three-quarter lags between funding and spending. Management remains focused on balancing growth investments with operational efficiency, expecting continued margin expansion as the COMET platform scales, and anticipates that improved biotech funding and resolution of NIH budget uncertainties will support acceleration in fiscal 2027 compared to the near-term flat to low single-digit growth environment.
No forward guidance provided.
Generated solely from the company's own reports listed below — not from third-party data. Hallucination risk is low. · Sources: 10-K, Q4 FY2026 Earnings Call
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 1.2B | 1.2B | 1.2B | 1.1B | 1.1B | 931M |
| Net Income | 109M | 73M | 168M | 285M | 272M | 140M |
| EPS | $0.70 | $0.46 | $1.05 | $1.76 | $0.42 | $0.22 |
| Free Cash Flow | 270M | 257M | 236M | 216M | 280M | 308M |
| ROIC | 5.5% | 3.5% | 8.6% | 13.0% | 15.2% | 13.7% |
| Gross Margin | 65.0% | 64.8% | 66.4% | 67.7% | 68.4% | 68.0% |
| Debt/Equity | 0.10 | 0.18 | 0.15 | 0.18 | 0.15 | 0.22 |
| Dividends/Share | $0.32 | $0.32 | $0.32 | $0.32 | $0.08 | $0.08 |
| Operating Income | 154M | 102M | 207M | 299M | 297M | 237M |
| Operating Margin | 12.7% | 8.4% | 17.8% | 26.3% | 26.8% | 25.5% |
| ROE | 5.3% | 3.7% | 8.3% | 15.5% | 16.7% | 9.5% |
| Shares Outstanding | 157M | 159M | 160M | 162M | 655M | 645M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 358M | 452M | 499M | 563M | 643M | 714M | 739M | 931M | 1.1B | 1.1B | 1.2B | 1.2B | 1.2B |
| Gross Margin | 70.3% | 67.9% | 67.5% | 66.5% | 67.2% | 66.3% | 65.4% | 68.0% | 68.4% | 67.7% | 66.4% | 64.8% | 65.0% |
| R&D | 31M | 41M | 45M | 54M | 55M | 62M | 65M | 71M | 87M | 92M | 97M | 99M | 97M |
| SG&A | 61M | 119M | 141M | 200M | 241M | 264M | 261M | 325M | 373M | 378M | 466M | 589M | 536M |
| EBIT | 160M | 147M | 151M | 121M | 136M | 147M | 157M | 237M | 297M | 299M | 207M | 102M | 154M |
| Op. Margin | 44.7% | 32.5% | 30.2% | 21.4% | 21.2% | 20.5% | 21.3% | 25.5% | 26.8% | 26.3% | 17.8% | 8.4% | 12.7% |
| Net Income | 111M | 108M | 104M | 76M | 126M | 96M | 229M | 140M | 272M | 285M | 168M | 73M | 109M |
| Net Margin | 31.0% | 23.8% | 20.9% | 13.5% | 19.6% | 13.4% | 31.0% | 15.1% | 24.6% | 25.1% | 14.5% | 6.0% | 9.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 376K | 0 | 87K | 142K | 9.9M | 3.8M | 12M | 0 | 0 |
| Returns on Capital | |||||||||||||
| ROIC | 21.1% | 15.1% | 11.2% | 7.7% | 11.2% | 9.0% | 8.4% | 13.7% | 15.2% | 13.0% | 8.6% | 3.5% | 5.5% |
| ROE | 14.5% | 13.1% | 12.1% | 8.3% | 12.4% | 8.6% | 18.0% | 9.5% | 16.7% | 15.5% | 8.3% | 3.7% | 5.3% |
| ROA | 13.5% | 11.2% | 9.5% | 5.7% | 8.0% | 5.5% | 11.7% | 6.5% | 11.9% | 11.6% | 6.3% | 2.8% | 4.3% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | 137M | 139M | 144M | 144M | 170M | 182M | 205M | 352M | 325M | 254M | 299M | 288M | 295M |
| Free Cash Flow | 123M | 119M | 127M | 129M | 149M | 156M | 153M | 308M | 280M | 216M | 236M | 257M | 270M |
| Owner Earnings | 114M | 96M | 92M | 69M | 78M | 71M | 90M | 215M | 182M | 108M | 149M | 137M | 154M |
| CapEx | 14M | 20M | 17M | 15M | 21M | 25M | 52M | 44M | 45M | 38M | 63M | 31M | 25M |
| Maint. CapEx | 19M | 37M | 43M | 60M | 64M | 78M | 83M | 88M | 101M | 107M | 112M | 110M | 100M |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 19M | 37M | 43M | 60M | 64M | 78M | 83M | 88M | 101M | 107M | 112M | 110M | 100M |
| CapEx/OCF | 10.1% | 14.3% | 11.7% | 10.6% | 12.3% | 14.0% | 25.2% | 12.6% | 13.8% | 15.0% | 21.0% | 10.8% | 8.6% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 45M | 47M | 48M | 47M | 48M | 48M | 49M | 50M | 50M | 50M | 50M | 50M | 50M |
| Dividend Yield | 1.6% | 1.4% | 1.4% | 1.2% | 1.0% | 0.7% | 0.6% | 0.1% | 0.1% | 0.4% | 0.4% | 0.5% | 0.4% |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 15M | 50M | 43M | 161M | 20M | 80M | 276M | 100M |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | 0.2% | 0.5% | 0.2% | 1.2% | 0.2% | 0.7% | 3.3% | 0.9% |
| Stock-Based Comp | 3.5M | 6.0M | 9.4M | 15M | 28M | 32M | 32M | 49M | 42M | 39M | 38M | 41M | 41M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||||||
| Net Debt | -330M | 35M | 87M | 186M | 157M | 339M | 174M | 130M | 8.9M | 146M | 166M | 184M | -9.8M |
| Cash & Equiv. | 319M | 55M | 64M | 92M | 122M | 101M | 147M | 199M | 173M | 181M | 152M | 162M | 210M |
| Long-Term Debt | 0 | 73M | 92M | 344M | 339M | 493M | 344M | 329M | 243M | 350M | 319M | 346M | 200M |
| Debt/Equity | 0.00 | 0.17 | 0.21 | 0.36 | 0.31 | 0.43 | 0.26 | 0.22 | 0.15 | 0.18 | 0.15 | 0.18 | 0.10 |
| Interest Coverage | N/A | 95.2 | 86.2 | 16.4 | 13.4 | 6.8 | 8.2 | 17.0 | 26.2 | 26.7 | 13.1 | 12.0 | 15.9 |
| Equity | 795M | 847M | 879M | 950M | 1.1B | 1.2B | 1.4B | 1.6B | 1.7B | 2.0B | 2.1B | 1.9B | 2.1B |
| Total Assets | 862M | 1.1B | 1.1B | 1.6B | 1.6B | 1.9B | 2.0B | 2.3B | 2.3B | 2.6B | 2.7B | 2.6B | 2.6B |
| Total Liabilities | 67M | 216M | 250M | 609M | 514M | 719M | 646M | 700M | 593M | 672M | 635M | 639M | -3.0M |
| Intangibles | 109M | 293M | 311M | 452M | 446M | 579M | 517M | 616M | 532M | 535M | 507M | 366M | 319M |
| Retained Earnings | 653M | 714M | 771M | 799M | 877M | 932M | 1.1B | 1.1B | 1.1B | 1.3B | 1.3B | 1.1B | 1.1B |
| Working Capital | 443M | 209M | 200M | 213M | 319M | 311M | 414M | 358M | 430M | 493M | 458M | 432M | 535M |
| Current Assets | 469M | 248M | 254M | 348M | 398M | 413M | 521M | 511M | 606M | 621M | 617M | 608M | 688M |
| Current Liabilities | 26M | 40M | 54M | 136M | 80M | 102M | 107M | 152M | 176M | 129M | 159M | 176M | 153M |
| Per Share Data | |||||||||||||
| EPS | 0.75 | 0.72 | 0.70 | 0.51 | 0.83 | 0.62 | 1.46 | 0.22 | 0.42 | 1.76 | 1.05 | 0.46 | 0.70 |
| Owner EPS | 0.77 | 0.64 | 0.62 | 0.46 | 0.51 | 0.46 | 0.57 | 0.33 | 0.28 | 0.67 | 0.93 | 0.86 | 0.98 |
| Book Value | 5.38 | 5.68 | 5.89 | 6.34 | 7.08 | 7.50 | 8.77 | 2.42 | 2.60 | 12.14 | 12.92 | 12.03 | 13.32 |
| Cash Flow/Share | 0.92 | 0.93 | 0.97 | 0.96 | 1.12 | 1.17 | 1.30 | 0.55 | 0.50 | 1.57 | 1.87 | 1.80 | 1.34 |
| Dividends/Share | 0.31 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.08 | 0.08 | 0.32 | 0.32 | 0.32 | 0.32 |
| Shares Out. | 147.9M | 149.1M | 149.2M | 149.8M | 152.3M | 155.4M | 157.4M | 645.2M | 655.3M | 162.0M | 160.1M | 159.5M | 156.5M |
| Valuation | |||||||||||||
| P/E Ratio | 28.2 | 32.3 | 36.7 | 55.8 | 42.8 | 81.9 | 43.0 | 125.6 | 51.2 | 42.6 | 67.6 | 112.2 | 102.2 |
| P/FCF | 25.4 | 29.1 | 30.1 | 33.0 | 36.1 | 50.3 | 64.2 | 228.4 | 198.6 | 56.3 | 48.1 | 32.1 | 41.6 |
| EV/EBIT | 17.3 | 23.9 | 26.1 | 36.8 | 40.8 | 56.0 | 63.3 | 74.8 | 47.0 | 41.2 | 55.8 | 80.8 | 72.8 |
| Price/Book | 3.9 | 4.1 | 4.4 | 4.5 | 5.0 | 6.7 | 7.1 | 11.3 | 8.2 | 6.2 | 5.5 | 4.3 | 5.4 |
| Price/Sales | 8.0 | 7.2 | 6.7 | 6.7 | 7.7 | 9.5 | 11.0 | 14.1 | 16.1 | 11.4 | 9.9 | 8.7 | 9.3 |
| FCF Yield | 3.9% | 3.4% | 3.3% | 3.0% | 2.8% | 2.0% | 1.6% | 1.7% | 2.0% | 1.8% | 2.1% | 3.1% | 2.4% |
| Market Cap | 3.1B | 3.5B | 3.8B | 4.2B | 5.4B | 7.9B | 9.9B | 17.6B | 13.9B | 12.2B | 11.4B | 8.2B | 11.2B |
| Avg. Price | 19.38 | 21.94 | 22.37 | 25.33 | 32.31 | 43.80 | 51.61 | 81.12 | 108.57 | 79.67 | 71.75 | 66.37 | 71.60 |
| Year-End Price | 21.14 | 23.31 | 25.71 | 28.33 | 35.43 | 50.56 | 62.56 | 108.98 | 85.00 | 75.06 | 71.00 | 51.62 | 71.60 |
BIO-TECHNE Corp passes 4 of 9 quality checks, suggesting mixed fundamentals.
BIO-TECHNE Corp trades at 138.1x trailing earnings, compared to its 15-year median P/E of 47.1x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 50.2x vs a median of 42.1x. The company's 5-year average ROIC is 10.8% with a gross margin of 67.1%. Total shareholder yield (dividends + buybacks) is 1.3%. At current prices, the estimated annualized return to fair value is +5.4%.
BIO-TECHNE Corp (TECH) has a net profit margin of 6.0%. This is a modest margin.
BIO-TECHNE Corp (TECH) generated $257 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
BIO-TECHNE Corp (TECH) has a debt-to-equity ratio of 0.18. This indicates a conservatively financed balance sheet.
BIO-TECHNE Corp (TECH) reported earnings per share (EPS) of $0.46 in its most recent fiscal year.
BIO-TECHNE Corp (TECH) has a return on equity (ROE) of 3.7%. This indicates moderate shareholder returns.
BIO-TECHNE Corp (TECH) has a 5-year average gross margin of 67.1%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 17 years of financial data for BIO-TECHNE Corp (TECH), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
BIO-TECHNE Corp (TECH) has a book value per share of $12.03, based on its most recent annual SEC filing.
Based on recent SEC filings and earnings disclosures, Management expects gradual improvement in end-market conditions as biotech funding translates into customer spending, academic markets normalize, and company-specific timing headwinds from cell therapy customers roll off in fiscal 2027. The spatial biology COMET platform is positioned for continued growth with record backlog exiting Q3 fiscal 2026, and GMP protein portfolio growth of nearly 50% year-over-year (excluding Fast Track cell therapy customers) is viewed as constructive for fiscal 2027 given typical two to three-quarter lags between funding and spending. Management remains focused on balancing growth investments with operational efficiency, expecting continued margin expansion as the COMET platform scales, and anticipates that improved biotech funding and resolution of NIH budget uncertainties will support acceleration in fiscal 2027 compared to the near-term flat to low single-digit growth environment.